Lexicon Pharmaceuticals, Inc. (LXRX) stock
LXRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 5/3087% above fair value
$1.78+0.03 (+1.71%)
Close on Nov 17, 2026Market cap $792.02MP/E –Yield –
Lexicon Pharmaceuticals total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Lexicon Pharmaceuticals's total debt was $51.44M at Jun 30, 2026. For fiscal 2025 it was $54.00M, down 46.2% from the year before. Over ten years it grew -6.2% a year on average. The highest annual figure on record is $245.67M in fiscal 2017.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $54.00M | -46.2% |
| FY2024 | Dec 31, 2024 | $100.30M | +0.8% |
| FY2023 | Dec 31, 2023 | $99.51M | +104.8% |
| FY2022 | Dec 31, 2022 | $48.58M | – |
| FY2021 | Dec 31, 2021 | $0 | -100.0% |
| FY2020 | Dec 31, 2020 | $11.65M | -95.3% |
| FY2019 | Dec 31, 2019 | $245.18M | +0.1% |
| FY2018 | Dec 31, 2018 | $245.00M | -0.3% |
| FY2017 | Dec 31, 2017 | $245.67M | +142.2% |
| FY2016 | Dec 31, 2016 | $101.45M | -1.4% |
| FY2015 | Dec 31, 2015 | $102.94M | -4.4% |
| FY2014 | Dec 31, 2014 | $107.67M | +392.1% |
| FY2013 | Dec 31, 2013 | $21.88M | -6.7% |
| FY2012 | Dec 31, 2012 | $23.45M | -5.8% |
| FY2011 | Dec 31, 2011 | $24.89M | -12.6% |
| FY2010 | Dec 31, 2010 | $28.48M | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $51.44M | -8.3% |
| Q1 FY2026 | Mar 31, 2026 | $49.68M | -50.7% |
| Q4 FY2025 | Dec 31, 2025 | $54.00M | -46.2% |
| Q3 FY2025 | Sep 30, 2025 | $56.51M | -43.4% |
| Q2 FY2025 | Jun 30, 2025 | $56.11M | -43.6% |
| Q1 FY2025 | Mar 31, 2025 | $100.70M | +0.8% |
| Q4 FY2024 | Dec 31, 2024 | $100.30M | +0.8% |
| Q3 FY2024 | Sep 30, 2024 | $99.90M | +0.6% |
| Q2 FY2024 | Jun 30, 2024 | $99.50M | +0.7% |
| Q1 FY2024 | Mar 31, 2024 | $99.87M | +104.5% |
| Q4 FY2023 | Dec 31, 2023 | $99.51M | +104.8% |
| Q3 FY2023 | Sep 30, 2023 | $99.27M | +317.4% |
| Q2 FY2023 | Jun 30, 2023 | $98.77M | +318.0% |
| Q1 FY2023 | Mar 31, 2023 | $48.85M | +108.1% |
| Q4 FY2022 | Dec 31, 2022 | $48.58M | – |
| Q3 FY2022 | Sep 30, 2022 | $23.78M | +80.5% |
| Q2 FY2022 | Jun 30, 2022 | $23.63M | +77.7% |
| Q1 FY2022 | Mar 31, 2022 | $23.48M | +75.5% |
| Q4 FY2021 | Dec 31, 2021 | $0 | -100.0% |
| Q3 FY2021 | Sep 30, 2021 | $13.17M | -35.2% |
| Q2 FY2021 | Jun 30, 2021 | $13.30M | -94.6% |
| Q1 FY2021 | Mar 31, 2021 | $13.38M | -94.5% |
| Q4 FY2020 | Dec 31, 2020 | $11.65M | -95.3% |
| Q3 FY2020 | Sep 30, 2020 | $20.32M | -91.7% |
| Q2 FY2020 | Jun 30, 2020 | $245.26M | +0.1% |
| Q1 FY2020 | Mar 31, 2020 | $245.22M | +0.1% |
| Q4 FY2019 | Dec 31, 2019 | $245.18M | +0.1% |
| Q3 FY2019 | Sep 30, 2019 | $245.13M | +0.1% |
| Q2 FY2019 | Jun 30, 2019 | $245.07M | -0.0% |
| Q1 FY2019 | Mar 31, 2019 | $245.03M | -0.2% |
| Q4 FY2018 | Dec 31, 2018 | $245.00M | -0.3% |
| Q3 FY2018 | Sep 30, 2018 | $244.95M | +144.6% |
| Q2 FY2018 | Jun 30, 2018 | $245.09M | +143.8% |
| Q1 FY2018 | Mar 31, 2018 | $245.40M | +142.9% |
| Q4 FY2017 | Dec 31, 2017 | $245.67M | +142.2% |
| Q3 FY2017 | Sep 30, 2017 | $100.15M | -1.7% |
| Q2 FY2017 | Jun 30, 2017 | $100.54M | – |
| Q1 FY2017 | Mar 31, 2017 | $101.02M | – |
| Q4 FY2016 | Dec 31, 2016 | $101.45M | – |
| Q3 FY2016 | Sep 30, 2016 | $101.83M | – |
See a number that looks wrong?